Lowering renal-vascular tissue-RAS activity in pathologic states such as diabetes and obesity with conventional pharmacotherapy (ACE inhibitor or angiotensin receptor blocker) has shown efficacy for the primary prevention of diabetic nephropathy [15,40,41]. The gene discussed is ACE; the disease is obesity due to melanocortin 4 receptor deficiency.